CORDIS · 190174464 · HORIZON
DNACA Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
Coordinator: ARCTIC THERAPEUTICS EHF (IS)
With an aging population and >55 million dementia cases worldwide; treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect. ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers. AT-001 is different in that it prevents aggregation of amyloid/ta…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
Co-funding: the European Union contributes €2.5M toward a total project budget of €3.6M — a funding rate of 70%, with the remainder covered by the consortium partners. The project runs over approximately 2 years from 2023-03-01 to 2025-02-28.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from IS
see all →- WHISPER — Wind Energy Harvesting for Ship Propulsion Assistance and Power101096577 · HORIZON · €9.0M
- MarineGuardian — Advancing Sustainable Fisheries and Marine Ecosystem Conservation in the Atlantic and Arctic Sea basin101212608 · HORIZON · €8.0M
- BioProtect — ADVANCING AREA-BASED MANAGEMENT TOOLS TO ACCELERATE THE PROTECTION AND RESTORATION OF MARINE BIODIVERSITY ACROSS THE EUROPEAN SEA BASINS101157341 · HORIZON · €8.0M
- FUTUREVOLC — A European volcanological supersite in Iceland: a monitoring system and network for the future308377 · FP7 · €6.0M
- FarFish — Responsive Results-Based Management and capacity building for EU Sustainable Fisheries Partnership Agreement- and international waters727891 · H2020 · €5.0M
- LIBBIO — Lupinus mutabilis for Increased Biomass from marginal lands and value for BIOrefineries720726 · H2020 · €4.9M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-EIC-ACC-BF funding scheme.
- What is the EU contribution?
- The European Commission contributes €2.5M toward a total project budget of €3.6M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-EIC-2022-ACCELERATOR-01.
- Who coordinates the project?
- The project is coordinated by ARCTIC THERAPEUTICS EHF (IS).
- What is the project timeline?
- The project runs from 2023-03-01 to 2025-02-28 — approximately 2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 190174464.